Urologie Vaterstetten - Dr. med. Block, Vaterstetten
Urologie Vaterstetten - Dr. med. Block, Vaterstetten
Urologie Vaterstetten - Dr. med. Block, Vaterstetten
Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.
YUMPU macht aus Druck-PDFs automatisch weboptimierte ePaper, die Google liebt.
Study # pts<br />
Median<br />
f/u(yr) EBRT LDR HDR BC LC FFDM CSS A B C D E F G H I J K L<br />
ASTRO BC definition, ICRU prescription pt, No androgen deprivation<br />
Hanks (61) 618 4,4 — — NR NR NR — — — — — NR<br />
Kestin (72) 322 2,5 — NS NS NS — — — NA — — — —<br />
Pollak (114) 301 3,3 — — NR NR — — — — — — — — — —<br />
Morton (100) 141 NS — NA NR NR — NA NA — — — —<br />
Nath (105) 110 > 5 — — NA NR NR — NA NA — —<br />
Zelefsky (160)<br />
Remaining studies<br />
1,078 11,0 — — NA NS NR — NR NA NA — NR NR — — —<br />
Bey (12) 164 2,7 — — NR NR NR — — — — — — —<br />
Fiveash (48) 180 3,0 — — NR NR NR — — — NR<br />
Hanks (60) 714 NR — — NR — NR — — — —<br />
Hanks (60) 1516 NR — — NA NR NR NR NA — NR NR NR<br />
Kupelian (2000) 1,041 2,7 — — NR NR — — — h —<br />
Lipsett (78) 96 NR — — NA NR NR NR NA NR —<br />
Lyons (82) 738 3,4 — — NR NR NR — — — — —<br />
Magrini (82) 208 5,7 — — NR NR NR NR — —<br />
Neglia (106) 154 4,6 — — NA NS NR NR — NR NA — — — —<br />
Perez (111) 195 4,6 — — NA NR NR NA — NR —<br />
Pollack (115) 1,127 4,3 — — NR NR NR — — — — NS<br />
Roach (124) 50 2,0 — — NR NR NR — NR<br />
Shipley (134) 202 5,0 — — NR NR NS — — — — — —<br />
Stock (136) 134 2,7 — — NR NR NR — NA — — — — — —<br />
Valicenti (143) 1,465 9,0 — — NA NR — NA<br />
Zelefsky (159) 743 3,0 — — NR NR NR — — — — — — —<br />
Abbreviation: NR = not reported; NS = not statistically significant; NA = not applicable; EBRT = external beam irradiation; LDR = low-dose-rate brachytherapy; = Statistically significant improvement; HDR = highdose-rate<br />
brachytherapy; BC = biochemical control; LC = local control; FFDM = freedom from distant metastasis; CSS = cause-specific survival; A = retrospective study or prospective nonrandomized trial; B =<br />
multiple centers; C = shorter follow-up in patients with higher dose; D = non-ASTRO Consensus Panel definition of biochemical failure; E = non-ICRU prescription point (i.e., center of prostate) in some or all patients;<br />
F = some patients received androgen deprivation as part of initial therapy; G = some patients with no pretreatment PSA; H = unequal prognostic factors in dose groups; I = RT technique changed over time; J =<br />
difference in RT technique for high-dose vs. low-dosegroup; K = pelvic RT in some patients; L = no data on complication rates in high-dose group.<br />
Tab. 17: Überprüfung der Datenqualität [entnommen aus (144)]<br />
51